Fruit Juice, Organic Anion Transporting Polypeptides, and Drug Interactions in Psychiatry

Andrade, Chittaranjan

doi:10.4088/jcp.14f09572

Cited by 13 publications

(11 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Dietary sources of vitamin K, such as spinach or broccoli, have been shown to cause a pharmacodynamic antagonism of warfarin thereby causing a need to increase the dosage requirement for warfarin. Grapefruit juice contains a bioflavonoid that inhibits CYP3A (define), an enzyme that is involved in the metabolism of many drugs (Andrade, 2014;Hanley, et al, 2011). Such interaction can cause a 5-fold increase in the bioavailability of some drugs (Mason, 2010).Especially, orally-administered drugs such as felodipine that are metabolized by CYP3A enzymes (Hanley et al, 2011).…”

Section: Background and Significancementioning

confidence: 99%

Knowledge, Attitudes and Awareness of Food and Drug Interactions among Nurses with Different Levels of Experience

Okunji¹

2015

IJN

View full text Add to dashboard Cite

Aim: To examine the knowledge, attitudes and awareness of food and drug interactions (FDI) among nurses with different levels of experience in their day to day practices. Background: The 2004 Institute of Medicine report (IOM), "Keeping Patients Safe," recognized the nursing profession as playing a critical role in patient safety (Dunton, 2007;McHugh & Lake, 2010). Although new nurses possess a strong theoretical knowledge of nursing, experience from practice is important in providing a safer level of practice (Hill, 2010).The retention of experienced nurses in practice, would require a continuous, career-long learning (Hill, 2010).Medical errors resulting in Adverse Drug Reactions (ADRs), pose a significant public health problem. Studies on the knowledge, attitudes and awareness of FDI among nurses with different levels of experience are lacking. Methods: This was a cross sectional study which included a structured questionnaire. The study included a convenience sample of 278 nurses divided into 5 groups with different levels of experience: 0-4 years (66); 5-9 years (75); 10-14 years (45); 15-19 years (41); and ≥20 years. Results: There was statistical difference in knowledge and attitude to FDI among the 5 groups. 72.3 % of nurses had not observed food and drug interaction during their practice. Conclusion: The five groups all scored low in their knowledge of FDI. Most of the participants recommended in-house training on FDI every six (6) months.There is a significant difference in the knowledge of FDI among the five groups with different levels of nursing experience.

show abstract

Section: Background and Significancementioning

confidence: 99%

Knowledge, Attitudes and Awareness of Food and Drug Interactions among Nurses with Different Levels of Experience

Okunji¹

2015

IJN

View full text Add to dashboard Cite

show abstract

“…For example, dietary sources of vitamin K, such as spinach or broccoli, have been shown to cause a pharmacodynamic antagonism of warfarin thereby causing a need to increase the dosage requirement for warfarin. Grapefruit juice contains a bioflavonoid that inhibits CYP3A, an enzyme that is involved in the metabolism of many drugs (Andrade, 2014;Hanley, et al, 2011). Concomitant administration of grapefruit with drugs that are metabolized by CYP3A enzymes can cause a 5-fold increase in the bioavailability of such drugs (Mason, 2010).…”

Section: Introductionmentioning

confidence: 99%

Knowledge of Food and Drug Interactions among Nurses: Assessment Strategy for Continuing Education

Enwerem¹,

Okunji²

2016

IJHE

View full text Add to dashboard Cite

The effect of medication errors on patient quality care and safety is a critical ongoing concern requiring solutions. Although medication safety has been a concern of all healthcare professions, registered nurses play an important role in medication safety as patients' advocates. A cross sectional study with structured questionnaire on common FDI found in the medical journal was used in this study. The questionnaire consisted of 37 questions (dichotomous and multiple choice questions). A convenience sample of 271 nurses from different inpatient community nursing units (60 medical surgical, 60 telemetry, 29 Intensive care (ICU), 21 emergency, and 101 'others') across the DC-MD-VA metropolitan areas were recruited for this study. The data was subjected to descriptive analysis. The study protocol was approved by the Office of Regulatory, Research Compliance, Howard University. The result, showed no significant differences in the knowledge of FDI among the 5 groups of registered nurses. The authors propose continuing education for all nurses to update dosage calculation, follow drug administration protocol and enhance knowledge of pharmacology as avenues to reduce medication error. The authors also recommend that future studies focus on a larger sample size, inclusion of more associated FDI variables and use of high level statistical analysis.

show abstract

“…In addition, participants refrained from drinking fruit juices 4 hours after dosing to avoid potential inhibitory effects on absorption mediated by organic anion transporters. 9 Blood samples for PK analysis were collected pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 8, 12, 24, 36, 48 and 72 hours post-dose.…”

Section: Study 1001 Designmentioning

confidence: 99%

Safety, pharmacokinetics and pharmacodynamics of TAK‐418, a novel inhibitor of the epigenetic modulator lysine‐specific demethylase 1A

Yin

Arkilo

Khudyakov

et al. 2021

Brit J Clinical Pharma

View full text Add to dashboard Cite

Funding informationThese studies were funded by Takeda Development Center Americas Aims: Dysregulation of histone methylation epigenetic marks may result in intellectual and developmental disability, as seen in Kabuki syndrome. Animal data suggest that increasing histone methylation by inhibiting lysine-specific demethylase 1A (LSD1) may improve cognitive outcomes in a model of Kabuki syndrome. TAK-418 is a novel LSD1 inhibitor, developed as a potential therapeutic agent for central nervous system disorders such as Kabuki syndrome. Here, we report safety, tolerability, pharmacokinetic and pharmacodynamic profiles of single and multiple doses of TAK-418 (ClinicalTrials.gov: NCT03228433, NCT03501069). Methods: Two randomized, double-blind, placebo-controlled, phase 1 studies of oral TAK-418 were performed, a first-in-human single-rising-dose (SRD) study (5-60 mg) in healthy adult male and female volunteers (placebo, n = 10; TAK-418, n = 30), and an SRD (120-160 mg) and multiple-rising-dose (MRD) study (20-160 mg once daily for 10 days) in healthy female volunteers (placebo, n = 2 [SRD] and n = 6 [MRD]; TAK-418, n = 6 [SRD] and n = 18 [MRD]).Results: TAK-418 was well tolerated. No clinically significant changes in laboratory test results or vital signs were observed and no serious adverse events were reported. TAK-418 had a nearly linear pharmacokinetic profile, with rapid absorption and short terminal half-life across the evaluated dose range. No obvious accumulation was observed after daily administration for 10 days. Administration with food delayed peak plasma concentrations but overall exposure was unaffected. TAK-418 rapidly crossed the blood-brain barrier and generally showed a dose-dependent response in the peripheral pharmacodynamic biomarker formyl-flavin adenine dinucleotide. Conclusion:The brain-penetrant LSD1 inhibitor TAK-418 was well tolerated, with pharmacokinetic and pharmacodynamic effects that support further investigation.

show abstract

Fruit Juice, Organic Anion Transporting Polypeptides, and Drug Interactions in Psychiatry

Cited by 13 publications

References 24 publications

Knowledge, Attitudes and Awareness of Food and Drug Interactions among Nurses with Different Levels of Experience

Knowledge, Attitudes and Awareness of Food and Drug Interactions among Nurses with Different Levels of Experience

Knowledge of Food and Drug Interactions among Nurses: Assessment Strategy for Continuing Education

Safety, pharmacokinetics and pharmacodynamics of TAK‐418, a novel inhibitor of the epigenetic modulator lysine‐specific demethylase 1A

Contact Info

Product

Resources

About